Will I be prescribed a GLP-1 if I come here?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Sometimes. A GLP-1 is prescribed when the FDA label criteria are met and nothing else has been found that better explains the weight. Wegovy and Zepbound are labelled for adults with a BMI of 30 or above, or 27 and above with a weight related condition. A no is a legitimate result of an evaluation, not a refusal to help.
Get urgent care if: you are taking a GLP-1 medication and develop any of the following.
- Severe, persistent abdominal pain, with or without vomiting, which may radiate to the back and can indicate pancreatitis
- Vomiting that stops you keeping fluids down, with dizziness or reduced urine output
- Swelling of the face, lips or tongue, or difficulty breathing, which can indicate a severe allergic reaction
- Severe upper right abdominal pain with fever or yellowing of the skin or eyes, which can indicate gallbladder disease
Sometimes yes, sometimes no, and both are ordinary results of an evaluation. A GLP-1 receptor agonist is prescribed when the labelled indication is met, no contraindication applies, and nothing else has been found that explains the weight better. It is not prescribed on request, and it is not withheld on principle. The evaluation decides, and the evaluation happens before the prescription rather than after it.
What the eligibility criteria are
The criteria come from the FDA labels, not from the practice. Wegovy is indicated for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight related comorbid condition. Zepbound carries the same adult thresholds and is additionally indicated for moderate to severe obstructive sleep apnea in adults with obesity. Both are contraindicated in a personal or family history of medullary thyroid carcinoma and in multiple endocrine neoplasia syndrome type 2.
When a GLP-1 is the wrong tool
A GLP-1 can be the wrong tool even when the BMI qualifies. When untreated hypothyroidism, a recently started antipsychotic, high dose glucocorticoids or untreated sleep apnea are driving the gain, the driver is treated first, because the drug lowers the weight without touching the cause. In pregnancy, planned pregnancy or breastfeeding it is not appropriate. Where there is active purging or untreated binge eating, a medication built around appetite suppression can tighten restriction and make the disorder worse. And in someone unable to eat adequate protein or do resistance training, more of the weight lost will be muscle than it should be.
What a no actually means
A decision not to prescribe is not the end of treatment. It normally arrives with the alternative attached: levothyroxine where the thyroid is the problem, a medication change made jointly with your psychiatrist, treatment of sleep apnea, metformin where insulin resistance dominates, or eating disorder treatment first with the weight question revisited afterwards. If a compounded product is what you were planning to use instead, the FDA has documented dosing errors with compounded semaglutide serious enough to require hospitalisation.
| What you bring | Likely answer |
|---|---|
| BMI 32, prediabetes, normal thyroid, no contraindication | A GLP-1 is on the table at the first or second visit |
| BMI 28 with no weight related condition | Does not meet the labelled indication; workup first |
| BMI 34 with a TSH of 14 mIU/L | Treat the hypothyroidism, then reassess the weight |
| BMI 31, planning pregnancy this year | Not appropriate now; a different plan is built |
| BMI 36 with a family history of medullary thyroid carcinoma | Contraindicated; other agents considered |
| BMI 33 with moderate to severe obstructive sleep apnea | Tirzepatide carries a labelled indication for this |
If you are coming specifically for a GLP-1, bring what lets the decision be made in one visit: current height and weight, a recent TSH, your full medication list with doses, any personal or family history of thyroid cancer or MEN 2, and whether pregnancy is possible. You will get a yes or a no with a reason attached, and if it is a no, the reason comes with what happens instead.
The clinical detail
Titration on both labels is deliberately slow. Semaglutide for weight management starts at 0.25 mg once weekly and escalates over at least 16 weeks to a maintenance dose of 2.4 mg once weekly. Tirzepatide starts at 2.5 mg once weekly for four weeks, then 5 mg, with increases of 2.5 mg no sooner than every four weeks to a maximum of 15 mg once weekly.
Warnings that apply to both: acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, diabetic retinopathy complications in patients with type 2 diabetes, hypoglycaemia when combined with insulin or a sulfonylurea, and delayed gastric emptying relevant to planned anaesthesia. Tirzepatide can reduce the efficacy of oral hormonal contraceptives, and the label advises a barrier method or a non-oral contraceptive for four weeks after starting and after each dose increase.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- WEGOVY (semaglutide) injection, prescribing information. U.S. Food and Drug Administration
- ZEPBOUND (tirzepatide) injection, prescribing information. U.S. Food and Drug Administration
- Pharmacological Management of Obesity, clinical practice guideline. Endocrine Society
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration
- Hypothyroidism (Underactive Thyroid). National Institute of Diabetes and Digestive and Kidney Diseases
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.